I Inhibrx Biosciences, Inc.: insider trades · United States · SEC (Form 4) Discover the full management transaction log of Inhibrx Biosciences, Inc., a listed issuer based in United States. Shares are quoted on US US, under the authority of SEC (Form 4). Market capitalisation: €1.4bn. The latest transaction was disclosed on 28 March 2025 (Don). Among the most active insiders: Kayyem Jon Faiz. All data is openly available.
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Last declaration on 28 March 2025
All Executives21 Thresholds0 Prospectus0 Other0
Declarations 21 total
● Director · Executives · 27 Mar 2025
90,000 shares 0Common Stock SEC:0002007919-25-000025:0
● Director · Executives · 16 Dec 2024
500,000 shares 0Common Stock SEC:0002007919-24-000068:0
● Director · Executives · 6 Dec 2024
52,000 shares 0Common Stock SEC:0002007919-24-000066:0
▲ Director · Executives · 19 Nov 2024
34,843 shares @ US$14.2269 20.4% of flow Common Stock SEC:0002007919-24-000064:0
Ideal exit: 16 Aug 2025 (T+270) ▲ Director · Executives · 3 Oct 2024
6,667 shares @ US$15.00 49.4% of flow Common Stock SEC:0002007919-24-000051:0
Ideal exit: 30 Jun 2025 (T+270) ▲ Chief Executive Officer · Executives · 12 Sept 2024
26,963 shares @ US$15.05 31.4% of flow Common Stock SEC:0002007919-24-000049:0
Ideal exit: 9 Jun 2025 (T+270) ▲ Director · Executives · 10 Sept 2024
179 shares @ US$15.00 1.3% of flow Common Stock SEC:0002007919-24-000047:0
Ideal exit: 7 Jun 2025 (T+270) ▲ Chief Executive Officer · Executives · 6 Sept 2024
26,000 shares @ US$15.29 30.7% of flow Common Stock SEC:0002007919-24-000045:0
Ideal exit: 3 Jun 2025 (T+270) ▲ Chief Executive Officer · Executives · 29 Aug 2024
10,000 shares @ US$14.03 10.9% of flow Common Stock SEC:0001739614-24-000037:0
Ideal exit: 26 May 2025 (T+270) ▲ Director · Executives · 29 Aug 2024
7,140 shares @ US$14.00 49.2% of flow Common Stock SEC:0001739614-24-000035:0
Ideal exit: 26 May 2025 (T+270) ▲ Director · Executives · 28 Aug 2024
10,000 shares @ US$13.98 100.0% of flow Common Stock SEC:0002007919-24-000042:0
Ideal exit: 25 May 2025 (T+270) ▲ Director · Executives · 22 Aug 2024
15,188 shares @ US$12.89 100.0% of flow Common Stock SEC:0002007919-24-000040:0
Ideal exit: 19 May 2025 (T+270) ▲ Chief Executive Officer · Executives · 20 Aug 2024
27,055 shares @ US$12.97 27.0% of flow Common Stock SEC:0002007919-24-000038:0
Ideal exit: 17 May 2025 (T+270) ● Director · Executives · 24 Jun 2024
89,050 shares 0Common Stock SEC:0002007919-24-000024:0
▲ Director · Executives · 5 Jun 2024
49,284 shares @ US$17.23 34.0% of flow Common Stock SEC:0002007919-24-000008:0
Ideal exit: 2 Mar 2025 (T+270) ▲ Director · Executives · 31 May 2024
70,193 shares @ US$16.14 45.6% of flow Common Stock SEC:0002007919-24-000006:0
Ideal exit: 25 Feb 2025 (T+270) 13,316,140 shares Common Stock, par value $0.0001 per share SEC:0000950170-24-067359:0
◆ Chief Scientific Officer · Executives · 29 May 2024
433,888 shares Common Stock SEC:0000950142-24-001490:0
◆ Chief Executive Officer · Executives · 29 May 2024
621,548 shares Common Stock SEC:0000950142-24-001493:0
◆ Director · Executives · 29 May 2024
806,075 shares Common Stock SEC:0000950142-24-001492:0
◆ Director · Executives · 29 May 2024
149,564 shares Common Stock SEC:0000950142-24-001491:0